fbpx Skip to main content

THURSDAY, Nov. 19, 2020 (HealthDay News) — A low-cost, group-delivered lifestyle intervention is associated with a significantly lower risk for progression to type 2 diabetes among high-risk individuals, according to a study published online Nov. 2 in JAMA Internal Medicine.

Michael Sampson, M.D., from the Norfolk and Norwich University Hospital NHS Trust in the United Kingdom, and colleagues assessed whether a group-based lifestyle intervention (with or without trained volunteers with type 2 diabetes) reduced the risk for progression to type 2 diabetes in people at increased diabetes risk. Participants were randomly assigned to a control arm receiving usual care (178 individuals), a theory-based lifestyle intervention arm of six core and up to 15 maintenance sessions (INT; 424 individuals), or the same intervention with support from diabetes prevention mentors who were trained volunteers with type 2 diabetes (INT-DPM; 426 participants).

The researchers found that a total of 156 participants progressed to type 2 diabetes: 22.8 percent receiving usual care, 13.7 percent receiving INT, and 15.0 percent receiving INT-DPM. For type 2 diabetes incidence, there was no significant difference seen between the intervention arms (odds ratio [OR], 1.14; 95 percent confidence interval [CI], 0.77 to 1.7; P = 0.51). However, each intervention arm was associated with significantly lower odds of type 2 diabetes (INT: OR, 0.54 [95 percent CI, 0.34 to 0.85; P = 0.01]; INT-DPM: OR, 0.61 [95 percent CI, 0.39 to 0.96; P = 0.033]; combined: OR, 0.57 [95 percent CI, 0.38 to 0.87; P = 0.01]). For all glycemic levels, ages, and social deprivation groups, the effect size was similar. Intervention costs per participant were low at $153.

“We have now shown a significant effect in type 2 diabetes prevention, and we can be very optimistic that even a modest weight loss, and an increase in physical activity, in real-world programs like this have a big effect on the risk of getting type 2 diabetes,” Sampson said in a statement.

One author disclosed receiving personal fees from WW UK.

You May Also Like::  Childhood Insulin Levels Linked to Later Psychosis Risk

Abstract/Full Text (subscription or payment may be required)

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More